RNA NanoMed

Due to the rapid growth of the field of RNA and its potential applications including RNA therapeutics, it is encouraging to have an RNA journal that advances the field by bridging the fundamental research and application of RNA. The prediction that RNA will become the third milestone in drug development has become a reality.  The establishment of an RNA journal related to this field by the International Society for RNA Nanotechnology and Nanomedicine (ISRNN) will be in line with the vision and mission of the society.

About Us

Editorial for the Inaugural Issue

The recent discovery of the critical role of  RNA in biological systems has revolutionized our understanding of molecular biology. It was found that only 1.5% of the human genome encodes for proteins, while the remaining 98.5% of the human genome mainly codes for small or long non-coding RNA. These unexpected findings have significantly transformed life sciences. Recent FDA approval of RNAi drugs and COVID-19 mRNA vaccines has highlighted the potential of RNA therapeutics in clinics. These breakthroughs underscore RNA's emergence as a cornerstone of modern medicine, as documented by Nobel Prize awards in Medicine or Physiology in 2023 and 2024. I am pleased that my 2014 publication predicted that RNA would be the third milestone in pharmaceutical drug development, which is now being realized.